Evaluation of Overall Health State, Treatment Burden, and Satisfaction with Insulin Efsitora Alfa (Efsitora) vs. Daily Comparator in Adults with Type 2 Diabetes in the QWINT Clinical Trial Program
Key Points
Treatment burden decreases significantly with insulin efsitora alfa compared to the daily comparator, enhancing patient satisfaction.
In QWINT trials, 80% of adults reported improved overall health state when using efsitora alfa versus other insulin.
Assessment included qualitative measures of treatment satisfaction over a six-month period among adults with type 2 diabetes.
Improving satisfaction with efsitora alfa may lead to better adherence to diabetic management strategies.
Evaluation of Overall Health State, Treatment Burden, and Satisfaction with Insulin Efsitora Alfa (Efsitora) vs. Daily Comparator in Adults with Type 2 Diabetes in the QWINT Clinical Trial Program | Synapse